Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 6,931 clinical trials

I Isabel Horton

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes. One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events seen in …

18-85 years All Phase 2

Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) progressively damages the nerve cells responsible for voluntary muscle movement. Over time, this leads to weakness in different muscles such as those used for movement or breathing. Breathing problems are one of the main causes of complications and reduced survival in people with ALS. This happens …

18-85 years All Phase N/A
S Study Office

Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis

The goal of this clinical trial is to determine whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong tracheostomy-free survival in people with amyotrophic lateral sclerosis (ALS).The main questions are:Does early and continuous LIC training slow the decline in forced vital capacity (FVC)? Does LIC training …

20 years and older All Phase N/A

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.

18-80 years All Phase 1
P Pascal CINTAS, MD PHD

Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis

Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The objective of …

18-99 years All Phase N/A
J Junfeng Lu, Dr.

Research on Wireless Brain Implant System for General Control of External Devices

The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive technologies, for paralyzed and amputee patients.WRS integrates a high-throughput, ultra-flexible neural electrode with an extremely small …

18-80 years All Phase N/A

Intestinal Microbiome Transplant in ALS

This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected. Blood samples will be used to determine changes in neurofilament light chain over time. Stool samples …

18 years and older All Phase 1/2
M Mariska J Vansteensel, PhD

Investigation on the Cortical Communication System

The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems.The main questions it aims to answer are efficient and stable control of Brain-Computer interface (BCI) functions for communication with attempted hand movements and …

18-70 years All Phase N/A
J Jimin Lee, PhD

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.The question is, What are the effects of communicative interaction on verbal communication in people with ALS?Participants will read words and sentences while …

18-90 years All Phase N/A
J Jiaxin Lin, PhD

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC). Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.

18 years and older All Phase 2

Simplify language using AI